This trial will test whether receiving the pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell therapy will help to create immunity against pneumococcus.
1 Primary · 5 Secondary · Reporting Duration: at 90 days and 180 days post CAR T therapy
Experimental Treatment
26 Total Participants · 1 Treatment Group
Primary Treatment: CD19 targeted CAR T Cell Therapy · No Placebo Group · Phase 2
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: